127 related articles for article (PubMed ID: 2060082)
1. Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in man.
Workman P; Newman HF; Bleehen NM; Ward R; Smithen CE
Cancer Chemother Pharmacol; 1991; 28(2):118-22. PubMed ID: 2060082
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.
Newman HF; Bleehen NM; Workman P
Br J Radiol; 1986 Apr; 59(700):423-5. PubMed ID: 2938660
[No Abstract] [Full Text] [Related]
3. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Maughan TS; Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1151-6. PubMed ID: 2140825
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
Roberts JT; Bleehen NM; Workman P; Walton MI
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1755-8. PubMed ID: 6480458
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer: evidence of diffusion from urine.
Awwad HK; el Badawy S; abd el Baki H; Zaghloul M; el Moneim Osman A; Akoush H; Fairchild K
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1083-4. PubMed ID: 2522918
[TBL] [Abstract][Full Text] [Related]
6. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.
Saunders MI; Dische S; Fermont D; Bishop A; Lenox-Smith I; Allen JG; Malcolm SL
Br J Cancer; 1982 Nov; 46(5):706-10. PubMed ID: 7171452
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Ro 03-8799 in mice bearing melanosarcoma: comparison with tumors without melanin.
Laurent F; Canal P; Soula G
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1101-3. PubMed ID: 2703390
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
9. The reversible N-oxidation of the nitroimidazole radiosensitizer Ro 03-8799.
Walton MI; Bleehen NM; Workman P
Biochem Pharmacol; 1985 Nov; 34(21):3939-40. PubMed ID: 4062968
[No Abstract] [Full Text] [Related]
10. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Ward R; Workman P; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts.
Taghian A; Lespinasse F; Guichard ME
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1535-40. PubMed ID: 1834621
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of Ro 03-8799: racemic mixture and enantiomers.
Newman HF; Dunphy EP; Bleehen NM; Dische S; Saunders MI; Des Rochers C; Workman P; Lenox-Smith I; Smithen CE
Br J Radiol; 1986 Oct; 59(706):997-9. PubMed ID: 3768642
[TBL] [Abstract][Full Text] [Related]
13. Effects of localised tumour hyperthermia on pimonidazole (Ro 03-8799) pharmacokinetics in mice.
Walton MI; Bleehen NM; Workman P
Br J Cancer; 1989 May; 59(5):667-73. PubMed ID: 2736198
[TBL] [Abstract][Full Text] [Related]
14. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.
Walton MI; Bleehen NM; Workman P
Br J Cancer; 1987 May; 55(5):469-76. PubMed ID: 3606940
[TBL] [Abstract][Full Text] [Related]
15. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity.
Oya N; Shibamoto Y; Sasai K; Shibata T; Murata R; Takagi T; Iwai H; Suzuki T; Abe M
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):119-27. PubMed ID: 7642409
[TBL] [Abstract][Full Text] [Related]
16. [Radiosensitizing effects of nitroimidazole derivative, KIN-804].
Tada T
Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Jan; 55(1):70-5. PubMed ID: 7899069
[TBL] [Abstract][Full Text] [Related]
17. Accelerated elimination of pimonidazole following microsomal enzyme induction in mice: a possible approach to reduced neurotoxicity of the pimonidazole-etanidazole combination.
Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1011-4. PubMed ID: 2522916
[TBL] [Abstract][Full Text] [Related]
18. The uptake of the radiosensitizing compound Ro 03-8799 (Pimonidazole) in human tumors.
Dische S; Bennett MH; Orchard R; Stratford MR; Wardman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1089-92. PubMed ID: 2703388
[TBL] [Abstract][Full Text] [Related]
19. The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations.
Saunders MI; Anderson PJ; Bennett MH; Dische S; Minchinton A; Stratford MR; Tothill M
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1759-63. PubMed ID: 6480459
[TBL] [Abstract][Full Text] [Related]
20. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):677-84. PubMed ID: 2843488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
